Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes

Journal of Vascular Surgery

Volumn 28, Issue 6, 1998, Pages 1024-1032

  Avena, R ^a   Mitchell, M E ^a   Nylen, E S ^a   Curry, K M ^a   Sidawy, A N ^a   Harris, L M ^a   Pappas, P J ^a   Youkey, J R ^a  

^a Vascular Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

ARTERY BLOOD FLOW; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BRACHIAL ARTERY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HYPOGLYCEMIA; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL;

EID: 0031774902     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-5214(98)70028-X     Document Type: Article

References (31)

1. LM Harris GL Faggioli R Shah N Koerner L Lillis P Dandona Vascular reactivity in patients with peripheral vascular disease Am J Cardiol 76 1995 207 212
2. RA. Cohen Dysfunction of vascular endothelium in diabetes mellitus Circulation 87 1993 V67 V76
3. MT Johnstone SJ Creager KM Scales JA Cusco BK Lee MA. Creager Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus Circulation 88 1993 2510 2516
4. P Clarkson DS Celemajer AE Donald M Sampson KE Sorensen M Adams Impaired vascular reactivity in insulindependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol J Am Coll Cardiol 28 1996 573 579
5. E Heron D Chemla JL Megnien JC Pourny J Levenson Y Lecarpentier Reactive hyperemia unmasks reduced compliance of cutaneous arteries in essential hypertension J Appl Physiol 79 1995 498 505
6. JH Pinkney CDA Stehouwer SW Coppack JS. Yudkin Endothelial dysfunction: cause of insulin resistance syndrome Diabetes 46 1997 S9 S13
7. MC Corretti GD Plotnick RA. Vogel Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound Am J Physiol 268 1995 H1397 H1404
8. Avena R, Curry KM, Sidawy AN, Simpkins JF, Neville RF, Mitchell ME, et al. The effect of occult diabetic status and oral glucose intake on brachial artery vasoactivity in patients with peripheral vascular disease. Cardiovasc Surg. In press.
9. R. Strout Insulin and atheroma 20-yr perspective Diabetes Care 13 1990 631 654
10. KG Reddy RN Nair HM Sheehan JM. Hodgson Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis J Am Coll Cardiol 23 1994 833 843
11. G Howard DH O'Leary D Zaccaro S Haffner M Rewers R Hamman Insulin sensitivity and atherosclerosis Circulation 93 1996 1809 1817
12. K Matsumoto S Miyake M Yano Y Ueki Y Yamaguchi S Akazawa Insulin resistance and arteriosclerosis obliterans in patients with NIDDM Diabetes Care 20 1997 1738 1743
13. SM Haffner H. Miettinen Insulin resistance implications for type II diabetes mellitus and coronary heart disease Am J Med 103 1997 152 162
14. MN Ghazzi JE Perez TK Antonucci JH Driscoll SM Huang BW Faja Cardiac and glycemic benefits of troglitazone treatment in NIDDM Diabetes 46 1997 433 439
15. RR. Henry Effects of troglitazone on insulin sensitivity Diabet Med 13 1996 S148 S150
16. K Berkowitz R Peters SL Kjos J Goico A Marroquin ME Dunn Effects of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM Diabetes 45 1996 1572 1579
17. T Antonucci R Whitcomb R Mclain D. Lockwood Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone Diabetes Care 20 1997 188 193
18. Y Iwamoto K Kosaka T Kuzuya Y Akanuma Y Shigeta T. Kaneko Effects of troglitazone, a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy Diabetes Care 19 1996 151 156
19. S Kumar AJM Boulton H Beck-Nielsen F Berthezene M Muggeo B Persson Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients Diabetologia 39 1996 701 709
20. MI Harris WC Hadden WC Knowler PH. Bennett International criteria for the diagnosis of diabetes and impaired glucose tolerance Diabetes Care 8 1995 562 567
21. EA Forsyth HM Aly SF Najjar RF Neville AN. Sidawy Transforming growth factor b 1 inhibits the proliferative effect of insulin on human infragenicular vascular smooth muscle cells J Vasc Surg 25 1997 432 436
22. Avena R, Mitchell ME, Neville RF, Sidawy AN. The additive effects of glucose and insulin on the proliferation of infragenicular vascular smooth muscle cells. J Vasc Surg. In press.
23. MB. Davidson Clinical implications of insulin resistance syndromes Am J Med 99 1995 420 426
24. 2+) ATPase activity: a possible etiology of type B insulin resistance Endocrinology 126 1990 45 52
25. 2+ currents and not endothelial nitric oxide production Diabetes 46 1997 659 664
26. R Joannides WE Haefeli L Linder V Richard EH Bakkali C Thuillez Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo Circulation 91 1995 1314 1319
27. SB Williams JA Cusco MA Roddy MT Johnstone MA. Creager Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus J Am Coll Cardiol 27 1996 567 574
28. U Scherrer D Randin P Vollenweider L Vollenweider P. Nicod Nitric oxide release accounts for insulin's vascular effects in humans J Clin Invest 94 1994 2511 2515
29. RE Law WP Meehan XP Xi K Graf DA Wulhrich W Coats Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia J Clin Invest 98 1996 1897 1905
30. K Graf XP Xi WA Hsueh RE. Law Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells FEBS Lett 400 1997 119 121
31. P Peraldi M Xu BM. Spiegelman Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling J Clin Invest 100 1997 1863 1869